Skip to main content
SpringerLink
Log in

Tisotumab Vedotin: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Tisotumab vedotin (Tivdak™) is an antibody-drug conjugate comprising a fully human monoclonal antibody specific for tissue factor (TF-011) conjugated to monomethyl auristatin E (MMAE) that has been engineered to target tissue factor expressing tumours. Based on the results of a phase II trial, tisotumab vedotin has been granted accelerated approval in the USA for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This article summarizes the milestones in the development of tisotumab vedotin leading to this first approval.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(3):383–93.

    Article  Google Scholar 

  2. Alley SC, Harris JR, Cao A, et al. Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro [abstract no. 221]. In: 110th Annual Meeting of the American Association for Cancer Research. 2019.

  3. Breij EC, de Goeij BE, Verploegen S, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 2014;74(4):1214–26.

    Article  CAS  Google Scholar 

  4. de Goeij BE, Satijn D, Freitag CM, et al. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther. 2015;14(5):1130–40.

    Article  Google Scholar 

  5. Genmab/Seagen. TIVDAKTM (tisotumab vedotin-tftv): US highlights of prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208s000lbl.pdf. Accessed 7 Oct.

  6. Seattle Genetics Inc. Seattle Genetics, Inc. announces corporate name change to Seagen Inc [media release]. 8 Oct 2020.

  7. Genmab. Genmab and Seattle Genetics to co-develop tisotumab vedotin for solid tumors [media release]. 29 Aug 2017.

  8. Data on file, Seagen Inc., 2021.

  9. Ventana Medical Systems. Ventana signs companion diagnostic agreement with international biotech for antibody drug conjugate program [media release]. 3 Apr 2014.

  10. Gray E, Hensley K, Allred S, et al. Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death [abstract no. 617]. J Immunother Cancer. 2020;8(Suppl 3):A371–2.

    Article  Google Scholar 

  11. Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609–19.

    Article  CAS  Google Scholar 

  12. Vergote I, Monk BJ, O’Cearbhaill RE, et al. Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study [abstract no. 723MO plus slides]. Ann Oncol. 2021;32(Suppl 5):S725–72.

    Google Scholar 

  13. Hong DS, Concin N, Vergote I, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res. 2020;26(6):1220–8.

    Article  CAS  Google Scholar 

  14. Vergote I, Monk BJ, Coleman RL, et al. Tisotumab vedotin versus investigator’s choice chemotherapy in second- or thirdline recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress) [abstract no. TPS5596]. J Clin Oncol. 2021;39(Suppl 15):TPS5596.

    Article  Google Scholar 

  15. Blank S, Mahdi H, Tehrani O, et al. InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer [abstract no. 882TiP]. Ann Oncol. 2020;31(S4):S646.

    Article  Google Scholar 

  16. Hong D, Fayette J, Birnbaum A, et al. innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors [abstract no. 930TiP]. Ann Oncol. 2021;32(Suppl 5):S816.

    Article  Google Scholar 

  17. Hong DS, Tehrani OS, Safran H, et al. SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors [abstract no. TPS3160]. J Clin Oncol. 2019;37(Suppl 15).

  18. Vergote I, Concin N, Mirza MR, et al. Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024) [abstract no. TPS6095]. J Clin Oncol. 2020;38(Suppl 15).

  19. US Food & Drug Administration. FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer [media release]. 20 Sep 2021. https://www.fda.gov.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Anthony Markham

Authors
  1. Anthony Markham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony Markham.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 506 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markham, A. Tisotumab Vedotin: First Approval. Drugs 81, 2141–2147 (2021). https://doi.org/10.1007/s40265-021-01633-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01633-8

Search

Navigation